Denosumab (Prolia ®, Xgeva ®) reversed cortical bone loss and increased bone mineral density, lowering wrist fracture rates in women with osteoporosis, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in Boston. (sciencedaily.com)
Denosumab treatment for three years fully reversed this bone loss, and two additional years of treatment resulted in further BMD gains that translated to significantly lower wrist fracture rates. (sciencedaily.com)
«The information highlights the great importance of working to develop strategies to prevent future fractures after an initial wrist fracture occurs.» (sciencedaily.com)